argenx Reports First Quarter 2023 Financial Results and Provides Business Update
Amsterdam, the Netherlands
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2023 financial results and provided a business update.
See where we started — and where we’re going — as we chart a new course together in immunology.
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at Argenx.
Get the latest news and info via our social media channels.